type 2 diabetes glp-1 receptor agonists are increasingly used to treat and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read GLP-1 trends 2025: real-world data,

If you have insomnia or a sleep disorder, appropriate evaluation and treatment should come first

Liu X, Yu Z, Huang X, Gao Y, Wang X, Gu J, et al

What should I do if I get a stomach bug and cannot keep my medication down

LEADER 1 A phase 3b, multicenter, international, randomized, double-blind, placebo-controlled study to assess the cardiovascular safety of Victoza

[32] studied the effects of Tirzepatide, a dual gastric inhibitory polypeptide-receptor agonist (GIP-RA) and GLP-1-RA, and gastric inhibitory polypeptide (GIP), on pancreatic adipose-tissue derived SVF cells in 2D and 3D culture

Dambrova M, Makrecka-Kuka M, Vilskersts R, Makarova E, Kuka J, Liepinsh E